Last Updated : May 19, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received Sort ascending | Date Recommendation Issued |
---|---|---|---|---|---|---|
Komboglyze | Saxagliptin + metformin | Diabetes Mellitus, Type 2 | Withdrawn | |||
Invokana | Canagliflozin | Diabetes Mellitus, Type 2 | Withdrawn | |||
Alimta | Pemetrexed | Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Genotropin | Somatropin | Growth hormone deficiency, adult | List with criteria/condition | Complete | ||
Genotropin | Somatropin | Growth hormone deficiency, children | List with criteria/condition | Complete | ||
Genotropin | Somatropin | Turner Syndrome | List with criteria/condition | Complete | ||
Picato | Ingenol mebutate | Actinic keratosis | Do not list | Complete | ||
Onglyza | Saxagliptin | Diabetes mellitus, type 2 | List with criteria/condition | Complete | ||
Latuda | Lurasidone | Schizophrenia | List with criteria/condition | Complete | ||
Mekinist | Trametinib | Metastatic Melanoma | Reimburse with clinical criteria and/or conditions | Complete |